Trial Profile
Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Combined in Vitro and Ex Vivo Dose Finding Study - APIXART
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Phlebitis; Thrombophlebitis
- Focus Pharmacodynamics
- Acronyms APIXART
- 14 Sep 2016 New trial record